PRELUDE THERAPEUTICS INC (PRLD) Stock Income Statement
USA - NASDAQ:PRLD - US74065P1012 - Common Stock
1.5 USD
-0.08 (-5.06%)
1.46 USD
-0.04 (-2.67%)
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.00M | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 146.71M | 132.28M | 123.54M | 113.74M | 58.76M | |||
| Research and Development | 118.00M | 103.39M | 92.89M | 86.78M | 48.18M | |||
| Selling, General, and Administrative Expenses | 28.72M | 28.88M | 30.65M | 26.96M | 10.59M | |||
| Operating Income | -139.71M | -132.28M | -123.54M | -113.74M | -58.76M | |||
| Other Income/Expense | 12.54M | 10.45M | 8.10M | 2.04M | 1.83M | |||
| Income Before Taxes | -127.17M | -121.83M | -115.44M | -111.69M | -56.93M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -127.17M | -121.83M | -115.44M | -111.69M | -56.93M | |||
| EBITDA | -137.94M | -131.11M | -122.22M | -112.82M | -58.22M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.68 | -2.02 | -2.44 | -2.43 | -4.56 | |||
| Non GAAP EPS | -1.69 | -2.03 | -2.44 | -2.42 | N/A | |||
| Statistics | ||||||||
| Profit Margin | -1816.76% | N/A | N/A | N/A | N/A | |||
| Operating Profit Margin | -1995.91% | N/A | N/A | N/A | N/A | |||
All data in USD